Mizuno Y, Shimabukuro T, Fukuzawa N
Department of Neurology, Jichi Medical School, Tochigi, Japan.
Eur Neurol. 1988;28(2):84-6. doi: 10.1159/000116236.
Effects of indeloxazine, a new compound which has been though to block reuptake of serotonin and noradrenaline, on cerebrospinal fluid monoamine metabolites were evaluated in 11 patients with dementia. Treatment with 90 mg/day of indeloxazine for 6-8 weeks resulted in significant reduction in methoxyhydroxyphenylen glycol and 5-hydroxyindoleacetic acid in these patients. These findings are consistent with results reported in experimental animals. The mode of action with respect to changes in monoamine metabolites and therapeutic implications of this compound are discussed.
对11例痴呆患者评估了茚达品（一种被认为可阻断血清素和去甲肾上腺素再摄取的新化合物）对脑脊液单胺代谢产物的影响。每天用90毫克茚达品治疗6至8周，结果这些患者的甲氧基羟基苯乙二醇和5-羟基吲哚乙酸显著减少。这些发现与实验动物报道的结果一致。讨论了该化合物在单胺代谢产物变化方面的作用方式及其治疗意义。
